Abera Bioscience AB news

Abera Bioscience AB (“Company” or “Abera”) initiated research and development in immuno-oncology in 2021 with a first sub-goal to explore the potential of the company’s platform in the area and to carry out initial studies for further prioritization. In accordance with the press release regarding a pr

Abera Bioscience AB is a biotechnology company that develops vaccine candidates based on patented vaccine platforms. The latest vaccine platform makes it possible to produce single, or multiple, antigens in so-called protein bodies. Antigens are the pathogen-specific components of vaccines that elicit immune responses. Protein bodies are nano-sized protein particles.

The company is now entering into a partnership with an American university to drive the development of a vaccine candid

Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the EU’s international health call next year. The grant from Vinnova aims at activities to stre

Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the EU’s international health call next year. The grant from Vinnova aims at activities to stre

Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. An article was recently published in the peer-reviewed journal Microbial Cell Factories by researchers Trang H. Phan, Coen Kuijl and Peter van Ulsen of Vrije Universiteit Amsterdam in collaboration with Abera’s Dung T. Huynh, Wouter S.P. Jong and Joen Luirink. The authors identified ways to improve the